Ogilvy Healthworld

Share this article:
Ogilvy Healthworld
Ogilvy Healthworld
100 Avenue of the Americas,
New York, NY 10013-1687
Phone: 212-625-4000 · Fax:212-925-5965
Email: info@ogilvyhealthworld.com · Web: www.ogilvyhealthworld.com
Founded: 1986
Parent company: WPP, New York, N.Y.

Officers: Steven Girgenti, chairman of the board; Angela Rossetti, president; Martin Skelton, president, medical education; Michael Guarini, senior partner/managing director of healthcare; Chris Clark, EVP/managing director; Dona Just, EVP/director of client services; Steve Witt, EVP/creative director, copy; Steven Frederick, EVP/creative director, art; Frank Hone, EVP, global business group.

Healthcare accounts: Abbott; Advanced Medical Optics; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Johnson & Johnson (Ortho-McNeil); Kos; Lilly; Mead Johnson Nutritionals; Merck; Pfizer; Telik; Unilever; Wyeth.

Accounts gained (1): Wyeth

Accounts lost (1): Novartis

Services: Professional communications, consumer communications, medical education, direct marketing, publication planning, managed care, clinical trial recruitment, global business group.

New hires: Jim Woods, CFO.

Divisions: Professional Advertising, Consumer Advertising, Medical Education, Global Business.
Share this article:
close

Next Article in Agency Gallery

Email Newsletters

More in Agency Gallery

Private View: Creating Compelling Experiences

Private View: Creating Compelling Experiences

In today's multi-channel environment, game-changing ideas blend creativity and sensory ideation to create a meaningful customer experience

Putting consumers at the center of your universe

Putting consumers at the center of your universe

The question should be: How do you simplify and identify the moments that mean the most to customers?

Did "pay-to-play" confab help Zohydro approval?

Did "pay-to-play" confab help Zohydro approval?

US senators Joe Manchin (D-WV) and David Vitter (R-LA) are asking whether a "pay-to-play" meeting between drug industry executives and FDA officials influenced the agency's approval of Zohydro